<DOC>
	<DOCNO>NCT02085447</DOCNO>
	<brief_summary>This prospective study use concierge model customize adherence enhancement long-acting injectable antipsychotic ( CAL-Concierge ) 30 individual schizophrenia schizoaffective disorder risk treatment non-adherence homelessness . Like CAE-L approach , CAL-Concierge expect improve health outcome among vulnerable population schizophrenia even importantly , demonstrate use improve efficiency quality care typical practice setting .</brief_summary>
	<brief_title>A Concierge Model CAE Plus LAI Individuals With Schizophrenia Risk Treatment Non-adherence Homelessness</brief_title>
	<detailed_description>Psychotropic medication cornerstone treatment individual schizophrenia , rate full partial non-adherence exceed 60 % . There direct correlation non-adherence rate relapse schizophrenia ; average , non-adherent patient risk relapse 3.7 time great adherent counterpart . Long-acting injectable antipsychotic ( LAI ) medication improve adherence need combine quality behavioral program modify long-term attitude behavior . A recently complete study fund Reuter Foundation conduct investigator find novel customize psychosocial adherence enhancement intervention pair LAI ( CAE-L ) reduce rate homelessness , improve psychiatric symptom increase overall functioning vulnerable group individual . CAE manualized appear acceptable homeless people serious mental illness . However , spite promising result , CAE-L intervention important limitation barrier wide-spread future use public health setting . These limitation : 1 . CAE-L use PhD-level psychologist deliver behavioral part program . Many public-sector clinical setting limit number highly trained individual . As alternative , social worker could efficient way deliver CAE . 2 . CAE-L use haloperidol decanoate injectable medication . Unfortunately , akathisia -- distressing side effect , occur 40 % people . Use newer , well tolerate medication option could improve investigator approach . 3 . Logistic barrier prevent people stabilize well CAE-L continue improve functioning transition back regular care setting . It clear need mechanism facilitate successful `` hand-off '' individual benefit CAE-L maintenance therapy . A successful transition could substantial financial humanitarian cost-savings . To address obstacle preparation large-scale randomize control trial novel , blend intervention investigator propose conduct prospective study use concierge model customize adherence enhancement combine long-acting injectable antipsychotic ( CAL-Concierge ) individual schizophrenia risk treatment non-adherence homelessness . Like CAE-L approach , CAL-Concierge expect improve health outcome among vulnerable population schizophrenia even importantly , demonstrate use improve efficiency quality care typical practice setting .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Decanoic acid</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Individuals age 18 old schizophrenia schizoaffective disorder confirm Mini International Psychiatric Inventory ( MINI ) . The investigator use DSM5 concordant version MINI available time first study participant enrol . Individuals currently recently homeless ( within past 12 month ) per revise federal definition homelessness ( Homeless Emergency Assistance Rapid Transition Housing . In : Development DoHaU , ed2011 . ) Known medication treatment adherence problem identify Treatment Routines Questionnaire ( TRQ , 20 % missed medication past week past month ) Ability rat psychiatric rating scale . Willingness take longacting injectable medication Currently treatment Community Mental Health Clinic ( CMHC ) treatment set able provide mental health care study participation Able provide write , inform consent study participation . Individuals longacting injectable antipsychotic medication immediately prior study enrollment . Prior current treatment clozapine Medical condition illness , opinion research psychiatrist , would interfere patient 's ability participate trial Physical dependence substance ( alcohol illicit drug ) likely lead withdrawal reaction course study clinical opinion treat research psychiatrist Immediate risk harm self others Female currently pregnant breastfeed Individual already permanent support housing include comprehensive mental health service ( i.e . Housing First )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Homelessness</keyword>
	<keyword>Antipsychotic Drugs</keyword>
	<keyword>Antipsychotics</keyword>
	<keyword>Injectables</keyword>
	<keyword>Long Acting Injectable Antipsychotic</keyword>
	<keyword>Psychotic Disorders</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Medication Adherence</keyword>
	<keyword>Medication Non-Adherence</keyword>
	<keyword>Community Mental Health Centers</keyword>
</DOC>